This meeting took place in 2012
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics (D1)
Organizer(s) Paul W. Noble, Shelia M. Violette and Scott L. Friedman
March 30—April 4, 2012
Big Sky Resort • Big Sky, MT USA
Abstract Deadline: Nov 30, 2011
Late Abstract Deadline: Jan 5, 2012
Scholarship Deadline: Nov 30, 2011
Early Registration Deadline: Jan 30, 2012
Sponsored by Bayer USA Foundation, Celgene Corporation, GlaxoSmithKline UK, Hoffmann-La Roche, Inc. and Regulus Therapeutics Inc.
Summary of Meeting:
Fibrosis is a pathological process in which diseased tissue is replaced with excess extracellular matrix ultimately leading to organ scarring and failure, a final common pathway in many forms of chronic disease affecting multiple tissues. Currently, there are minimal and inadequate treatment options for fibrotic disease. There is an urgent need to understand the cellular, molecular and genetic basis of fibrosis in humans and develop animal models that replicate and illuminate this pathological process. There is also a need to identify prognostic markers of disease susceptibility, biomarkers of disease progression and improved technologies to monitor the effectiveness of new therapies. The goal of the Keystone Symposia meeting on Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics is to bring together researchers and clinicians in academia and industry to provide an integrated perspective of basic disease mechanisms, and to address the more pragmatic challenges associated with executing clinical trials and refining approaches to accelerate the clinical development of anti-fibrotic drugs.
View Meeting Program
Fibrosis is a pathological process in which diseased tissue is replaced with excess extracellular matrix ultimately leading to organ scarring and failure, a final common pathway in many forms of chronic disease affecting multiple tissues. Currently, there are minimal and inadequate treatment options for fibrotic disease. There is an urgent need to understand the cellular, molecular and genetic basis of fibrosis in humans and develop animal models that replicate and illuminate this pathological process. There is also a need to identify prognostic markers of disease susceptibility, biomarkers of disease progression and improved technologies to monitor the effectiveness of new therapies. The goal of the Keystone Symposia meeting on Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics is to bring together researchers and clinicians in academia and industry to provide an integrated perspective of basic disease mechanisms, and to address the more pragmatic challenges associated with executing clinical trials and refining approaches to accelerate the clinical development of anti-fibrotic drugs.
View Meeting Program
Scholarships/Awards
Early Career Investigator Travel Award Recipients
Colin Jamora
University of California, San Diego, USA
National Heart, Lung, and Blood Institute (NHLBI) Scholarship Recipients
Lee A. Borthwick
Newcastle University, UK
Wanchang Cui
University of Maryland, Baltimore, USA
Lisa Dominak
Cleveland Clinic, USA
Janusz Franco-Barraza
Fox Chase Cancer Center, USA
Virginia Hernandez Gea
Hospital Clinic of Barcelona, University of Barcelona, Spain
Jinu Kim
University of Nebraska Medical Center, USA
Thuy T. Le
University of Texas Health Science Center, Houston, USA
Stefania Lenna
Boston University, USA
Marlies Schippers
University of Groningen, Netherlands
